Infinimmune Partners with Merck to Discover Novel Human Antibody Therapeutics Using AI

Key Points

• Infinimmune's Anthrobody® platform combines human immune repertoire screening with AI-guided engineering
• The GLIMPSE™ antibody language model optimizes antibodies for therapeutic properties
• Collaboration targets multiple undisclosed disease targets designated by Merck
• Human-first approach enables discovery of novel antibodies not accessible through traditional methods

Full Details

Infinimmune, a biotechnology company based in Alameda, California, announced a collaboration with Merck (known as MSD outside the United States and Canada) to discover novel antibody therapeutics. Under the agreement, Infinimmune will use its proprietary Anthrobody® discovery platform, which integrates large-scale single-cell human immune repertoire screening with machine learning-guided antibody engineering. The GLIMPSE™ antibody language model enables AI-guided screening of human immune repertoires to identify and optimize antibodies for potency, manufacturability, and developability. This human-first approach allows discovery of antibodies directly from the human immune system, offering access to novel biology and promising therapeutic candidates that might not be found through traditional methods.